Insight has compiled a round-up of the main products available for myopia management in Australia in 2024, including some upgrades to existing treatment modalities.
Rodenstock releases MyCon 2
With MyCon, Rodenstock developed a solution to control the progression of myopia in children, and now, with MyCon 2, the company is going a step further by including the four individual position-of-wear parameters.
According to the lens manufacturer, MyCon 2 lenses offer improved imaging properties by customising the lens to the fit of the frame and thus to the child’s unique face. This approach includes the four individual wearing parameters, the pupil distance (PD), the pantoscopic tilt (PT), the corneal vertex distance (CVD) and the face form angle (FFA), which help to adapt the lens even more precisely. By using these parameters, “improved imaging properties can be achieved in the focus area of the lens while maintaining the effect of myopia control in the periphery”.
Rodenstock MyCon 2 lenses are available in index 1.5, 1.6, 1.67, and 1.74 in clear, tinted, polarised & ColorMatic which make the lenses both thinner and sleeker than many other myopia lenses on the market and well suited to high prescriptions, Rodenstock says.
Contact: (02) 9748 0988
Myopia Expert 700 – a trusted partner for myopia management
With axial length being the critical measurement in myopia management, the Myopia Expert 700 delivers a gold standard, non-invasive axial length measurement to help guide myopia management solutions and provide ongoing control.
Additionally, the instrument has a complete set of measurements for all myopia solutions. Covering the full spectrum, the Myopia Expert 700 captures key measurements necessary for the application of different myopia solutions, allowing the practitioner to recommend the optimum control solution to the patient.
These include: corneal topography, keratometry, fluorescein, pupillometry and white-to-white measurement.
Myopia Expert 700 is manufacturered by Essilor Instruments and is supplied to Australian practitioners through OptiMed.
Contact: sales@optimed.com.au
New 12-month data for ZEISS MyoCare lenses
ZEISS MyoCare lenses, released locally in 2023, are created on the basis of simultaneous competing blur, including a clear central zone and intermittent treatment rings within the functional zone of the lens. The distinctive freeform back surface, ZEISS ClearFocus Design, is designed to prevent hyperopic defocus for all directions of gaze.
During the recent Association for Research in Vision and Ophthalmology (ARVO) 2024 conference, ZEISS presented results from two ongoing multi-centre trials in China and Europe.
“We observed that the use of ZEISS MyoCare lenses significantly slowed progression of myopia when compared to single vision lenses. After 12 months of lens wear, the difference in myopia progression in Asian children with ZEISS MyoCare compared to single vision was SE: 0.31D and AL:0.13mm. The data represents a comprehensive evaluation of ZEISS MyoCare across multiple sites involving large samples and ethnic groups,” the company says.
“We are excited to announce that in addition to our six-month unconditional warranty, we have also expanded our product range from 1.5, 1.59 and 1.6 to now include the 1.67 index.”
Contact: visioncare.au@zeiss.com
Superior lens aesthetics and comfort at competitive price point
The MyoStock lens, launched by CR Labs in February 2024, is designed to combat myopia progression with Hexagon Implicated Defocus Segment (HIDS) technology.
It features a central clear viewing zone surrounded by hexagonal segments, which help slow eye elongation and reduce myopia progression.
“An in-house study shows a 45% decrease in myopia progression and a 53% reduction in axial elongation in children wearing MyoStock lenses,” CR says.
“With a thinner, aspheric design and blue light filter, MyoStock lenses offer superior aesthetics and comfort and competitive price point, making them an ideal choice for managing myopia.”
MyoStock also comes equipped with ultra-super, hydrophobic (USH) coating, making it resistant to fingerprints, oils, and scratches, and providing hydrophobic properties for easy maintenance.
Contact: info@crlabs.au
Myopia software now on Pentacam AXL wave
The Myopia Software available in the OCULUS Myopia Master has been expanded to work with the Pentacam AXL Wave, offering several key benefits for myopia detection and management.According to Designs For Vision, part of ParagonCare and the Australian and New Zealand distributor of this technology, it offers increased flexibility, with the software now able to process data from both devices. There’s also data exchange advantages, with the capability to share existing data between the two devices, improving efficiency in daily clinical work. Other features include:
- Comprehensive myopia package: Myopia Package combines crucial parameters to simplify myopia detection and management.
- Personalised risk assessment: the software incorporates the latest BHVI data to estimate future myopia progression based on individual factors such as age, gender, and ethnicity.
- Patient education support: software generates personalised reports detailing current myopia status and potential future outcomes, which can be used to educate patients about their condition.
- Improved reliability: by combining data from multiple sources and incorporating the latest research, the software offers more reliable myopia detection and management tools.
“This expanded functionality of the Myopia Software, along with its integration with the Pentacam AXL Wave, provides eyecare professionals with a more comprehensive and flexible toolset for managing myopia in their patients. The ability to exchange data between devices and generate personalised reports based on the latest research enhances the overall efficiency and effectiveness of myopia care,” DFV says.
Contact: 1800 225 307
See more, treat more with Optos technology
Optos says its Daytona device produces a 200° single-capture optomap retinal image of unrivalled clarity in less than ½ second. This fast, easy, patient friendly, ultra-widefield (UWF) imaging technology was designed for healthy eye screening and has been shown to improve practice flow and patient engagement.
Enhances Clinical Decision-making: Evaluation of the peripheral retina is critical for optimal patient management. optomap imaging is ideal for peripheral examinations. Published studies comparing field-of-view and clinical utility of various widefield imaging systems confirm optomap captures the widest clinically usable field of view and the most retinal pathology, Optos says.
Improves Practice Efficiency and Economics: Studies show that optomap images are faster to capture and easier to review than traditional patient examination techniques. optomap enables practitioners to differentiate their practice and add an additional revenue stream.
Contact: auinfo@optos.com
Essilor Stellest now backed by five-year data
A five-year clinical study of the Essilor Stellest lenses has demonstrated continued long-term efficacy in controlling myopia progression and axial elongation.
The controlled, prospective, randomised clinical trial which began in 2018 was conducted at the Eye Hospital of Wenzhou Medical University in Wenzhou, China. The age of the children at enrolment in 2018 was eight to 13 years old. To assess the long-term efficacy, the study was extended from the original two-year clinical trial to five years.
The data showed that Essilor Stellest lenses slowed myopia progression by 1.75D*1 and axial elongation by 0.72mm**1 on average over five years for all subjects, compared to the extrapolated control group, showing conclusive evidence of their efficacy in slowing down myopia progression in children in the fifth year.
The data also showed that the efficacy in slowing myopia progression and axial elongation was sustained in older children (up to 18 years old), as the children who completed the fifth-year study were aged between 13-18 years.
It is planned to continue the study for two more years, to gauge the seven-year myopia control efficacy of the lens.
NOTE: References available upon request.
Contact: marketing@essilor.com.au
Red-light offers new approach to management
The Eyerising Myopia Management Device is described by its manufacturer as a cutting-edge solution specifically designed for myopia management using low-level red-light technology.
Developed by Australian-based Eyerising International, it “delivers safe, non-invasive light therapy to the eyes, stimulating blood flow, which in turn thickens the choroid layer in patients with myopia”.
“This innovative treatment has shown promising results in slowing the progression of myopia in children aged three to 16 years old,” the company says. “The device is user-friendly, with a design and security features that make the treatment convenient for home use.”
The therapy requires two sessions per day, each lasting three minutes, making it simple to incorporate into daily routines without disruption, Eyerising International says.
“Backed by extensive research and clinical studies, Eyerising Myopia Management Device offers a scientifically validated approach to managing myopia, reducing the need for more invasive treatments,” it says. “This therapy provides an effective strategy for myopia management in your practice.”
Contact: info@eyerisinginternational.com
MiYOSMART offers ‘confidence through evidence’
MiYOSMART provides a robust and wide spectrum of evidence, empowering eyecare professionals to meet the needs of diverse patients with confidence, HOYA says. The award winning1-3 spectacle lenses have been shown to slow myopia progression by 60% in children aged 8 to 13,4 the company says.
Also, the findings of the six-year, long-term follow-up study showed the MiYOSMART spectacle lens myopia control effect is sustained over time for children wearing the lens, with an average cumulative myopia progression less than 1.00D and axial elongation 0.6 mm over six years in children that wore MiYOSMART for the duration of the study,5 according to HOYA.
“It also confirmed that patients who stop wearing the MiYOSMART spectacle lens show no rebound effects,”5 HOYA says.
MiYOSMART is available in clear and sun options. MiYOSMART The recently-released MiYOSMART Chameleon, photochromic spectacle lenses, are said to be the ideal all-in-one myopia solution. Rapidly adapting to the levels of sunlight, it provides children with as much protection as they need at any time and place.6,7,8
Meanwhile, MiYOSMART Sunbird, HOYA’s polarised spectacle lenses, are the ideal addition to MiYOSMART clear spectacle lenses for extra protection from intense sunlight and glare, 7,10 the company says.
NOTE: References available upon request.
Contact: ulli.hentschel@hoya.com
Master orthoK with Medmont meridia
The meridia advanced corneal topographer generates high-quality, reliable and precise topography maps – the key to successful orthokeratology (orthoK) design and fitting. Unlike other topographers that extrapolate data, it provides the practitioner with real topography data from limbus-to-limbus.
Proprietary composite topography capture provides users with a complete view of the cornea for utmost confidence in your orthoK lens design.
“Achieve the perfect fit in the way that suits you best with the meridia’s convenient lens design options. Use the effortless contact lens simulator, integrate with custom lens design software such as EyeSpace and WAVE, or send your data to your contact lens lab so they can design the lens for you,” manufacturer Medmont states.
“Assess and document fit at a glance with the meridia’s easy-to-interpret subtractive map function and powerful fluorescein imaging and video.”
The meridia is considered an indispensable tool for determining orthoK candidacy, designing lenses, evaluating fit and achieving quick orthoK lens success for myopia patients.
Contact: info@medmont.com
Backed by longest-running soft contact lens study in children
MiSight 1 day from CooperVision remains the only contact lens with US FDA approval for slowing the progression of childhood myopia.
The range covers -0.25D to -10.00D (0.50D steps after -6.00D) – which means it covers 99.97% of prescriptions for Asian children, and 99.97% for Caucasian children who have myopia and less than 1D of astigmatism,1 the company says.
MiSight 1 day contact lenses are also said to be backed by the longest-running soft contact lens study among children.
“This extraordinary study, also confirmed the overwhelming preference children have for contact lenses, giving optometrists the evidence to support their decision-making and parental conversations,” CooperVision says.
Reference: CVI Data on file, 2022. SERE coverage of childhood myopia prescriptions with MiSight 1 day for 104,810 eyes in Asia (China, Korea) and 116,336 eyes in Europe and USA aged 8-18 years.
Contact: cs@au.coopervision.com
Precision with Biometry OCT
B-OCT is an innovative method of using the Optopol REVO OCT device to measure ocular structure along eye axis. OCT biometry provides a complete set of biometry parameters: axial length, central cornea thickness, anterior chamber depth and lens thickness.
B-OCT is a software licence feature for the ‘REVO’ OCT available through OptiMed. It is considered an ideal tool for myopia control, with many Australian myopia management key opinion leaders successfully using this technology. All measurement callipers are shown on all boundaries of OCT images provided by REVO. Now, practitioners can visually verify, identify and, if required, make corrections as to which structure of the eye has been measured. With a simple cursor shift, it is possible to precisely set boundaries for every patient.
From now, ECPs can eliminate the common uncertainty as to how most optical biometers classify the boundaries in non-typical patients.
- 3 mm scan allows precise evaluation of retinal conditions
- 5 µm resolution gives the highest level of detail.
The REVO Biometry licence was recently updated to include progression analysis (retrospective data enabled) to provide a powerful management software package that includes normative database. Choroidal thickness evaluation will be available in the next software release, to help better evaluate treatment effectiveness.
Contact: sales@optimed.com.au
‘Myo’ freeform technology meets myopia management
MyoME, available through CR Labs, is a lens designed using ‘Myo Freeform’ technology and offers an exciting approach to managing the silent pandemic of childhood myopia, the company says.
According to CR, MyoMe is a peripheral defocus lens with a near addition. The lens is composed of a clear central zone. The nasal and temporal side of the lens incorporates areas of asymmetrical positive defocus to ensure light is focused in front of the retinal plane, effectively preventing axial elongation, and slowing down myopia progression.
A 2024 clinical trial investigated the efficacy of the MyoME lens in European children with myopia. The study found that at the 12-month review, MyoME had reduced axial elongation by 39%, in comparison to children wearing single vision lens,1 the company states.
“MyoME is the myopia management lens that has been developed and tested. Its freeform technology incorporates the research behind peripheral myopic defocus and asymmetric defocus to reduce axial elongation and slow down myopia progression,” CR says.
Reference: Sánchez-Tena, Miguel Ángel, et al. “Effectiveness of a Spectacle Lens with a Specific Asymmetric Myopic Peripheral Defocus: 12-Month Results in a Spanish Population.” Children 11.2 (2024): 177.
Contact: info@crlabs.au
More reading
Dr Joseph Paul delves into Specsavers ANZ’s myopia data
Myopia and seizing those sliding doors moments
